Muenter M D
Clin Neuropharmacol. 1986;9 Suppl 1:S23-36.
Treatment of Parkinson's disease is not difficult in the early stages of the disease; a therapeutic regimen of carbidopa-levodopa or possibly, a combination of carbidopa-levodopa and bromocriptine, provides the best therapeutic results. There is no reason to withhold carbidopa-levodopa therapy early in the disease. During the more advanced stages of the disease, in addition to meticulous titration of carbidopa-levodopa, the administration of a dopamine agonist (such as bromocriptine), amantadine, or an anticholinergic agent may be required in an attempt to smooth the therapeutic effect. All of these drugs, with the exception of amantadine, require small initial doses with subsequent cautious increases in dosage. Mental side effects are less likely to occur with carbidopa-levodopa therapy than with any of the other drugs.
帕金森病在疾病早期治疗并不困难；卡比多巴-左旋多巴治疗方案，或者可能是卡比多巴-左旋多巴与溴隐亭联合使用，能提供最佳治疗效果。在疾病早期没有理由不采用卡比多巴-左旋多巴治疗。在疾病的更晚期，除了对卡比多巴-左旋多巴进行细致的滴定外，可能还需要使用多巴胺激动剂（如溴隐亭）、金刚烷胺或抗胆碱能药物，以试图使治疗效果更平稳。除金刚烷胺外，所有这些药物都需要小剂量起始，随后谨慎增加剂量。与使用其他任何药物相比，卡比多巴-左旋多巴治疗产生精神方面副作用的可能性更小。
